NORWALK, Conn., June 17, 2014 /PRNewswire/ -- Tens of millions of Americans suffer from chronic digestive disorders. These growing patient populations are turning to the internet for treatment information on gastroesophageal reflux disease (GERD) and bowel incontinence. In the case of patients with GERD, an estimated 15 million Americans have daily symptoms, and approximately 30 percent of these patients have symptoms that are not well controlled by medications. Many of these patients are searching for a non-surgical solution.
With that patient in mind, Mederi Therapeutics, the maker of Stretta and Secca, redeveloped their product websites stretta-therapy.com and secca-therapy.com as educational tools where patients and the physicians who treat them can turn for information about conditions, diagnosis, and treatment options. This storytelling strategy addresses what patients and health care professionals need to know, allowing users to develop an understanding of how Stretta and Secca work to improve the dysfunction that causes chronic symptoms.
The Stretta site incorporates an overview of types of GERD and related conditions, including non-erosive reflux disease (NERD), extra esophageal reflux, and Barrett's Esophagus (BE). The site also explores current treatment options and reviews the continuum of care from drug therapy, to Stretta, to surgery. In addition to providing detailed information on Stretta, the site also features patient video testimonials that provide insight into the patient's experience with Stretta, and how Stretta has positively affected their GERD symptoms and improved their quality of life.
"When patients are informed about all available options and how they work, it's a win-win for patients and health care professionals," explained Sheila Doyle, Director of Marketing at Mederi. "We wanted to make it easy for our audience to get that information and provide education on the benefits of non-surgical options Stretta and Secca. Initial response has been outstanding – patients and physicians from all over the world have connected with us through the new platform."
Mederi Therapeutics manufactures and markets innovative medical devices Stretta® for GERD and Secca® for bowel incontinence. These outpatient, minimally invasive therapies use radiofrequency (RF) energy to treat the sphincter muscle at either end of the digestive system, offering improved function, fewer symptoms and improved quality of life. Stretta and Secca fill the treatment gap between medications and surgery.
For more information visit mederi-inc.com.
Contact: Julia Brannan
SOURCE Mederi Therapeutics